On a Mission
To Bring Safer Alternatives to Smokers
Parallax Development is a life sciences development company focused entirely on developing an innovative, multi-patented platform for delivering nicotine to smokers – and only smokers – in the safest ways possible.
Nicotine can be the solution
Our target is the addicted smoker who is trapped in a cycle of self-destruction. We believe harm reduction will save millions of lives that would otherwise be lost to smoking-related disease. Nicotine is not the problem. Smoking is. In fact, nicotine can be the solution.
It’s time to start
Fighting fire without fire
While smoking prevalence is declining, globally, more than 7 million people will still die this year from smoking – and 1 billion this century. That’s not acceptable.
Our product – which is still in development, but for which we have achieved significant proof of concept – leverages the most advanced technologies in pulmonary medicine. We will deliver nicotine via inhalation that is free of all combustion, ash and smell. It will never have any characteristics or flavours that are designed to appeal to kids or non-smokers.
Founded by Physicians
Who put people first
Our mission: To end the scourge of cigarette smoking with a safe and pure product. For those who can’t quit, we seek to replace every cigarette with a safer alternative, one that delivers an equivalent nicotine effect, but leaves no lasting scars.
Recently we entered into a strategic collaboration with Philip Morris International (PMI) to accelerate our mission. PMI has publicly committed themselves – and billions of dollars – to assure a smoke-free future. With their resources, we can develop our product faster than any other path. This is a race to save lives.
Meet our Team
Our Senior Management Team
Steven Ellis CEOBusiness executive in medical device and health care
- Howard Steinberg Executive Chairman
Business executive and investor
- Noe Zamel, MD, FRCPC, FCCP Co-Founder, Chief Medical Officer
Professor of Medicine, Respiratory Division, University of Toronto; and Director of Toronto’s Mount Sinai Hospital Pulmonary Function Laboratory
- Pat Tremaine VP Product Management & Communications
- Meaghan MacLean Director Product Management & Communications
- Douglas Thomson Director Manufacturing Planning
Our Board
- Howard Steinberg Executive Chairman
Business executive and investor
- Steven Ellis CEO
Business executive in medical device and health care
- Noe Zamel, MD, FRCPC, FCCP Co-Founder, Chief Medical Officer
Professor of Medicine, Respiratory Division, University of Toronto; and Director of Toronto’s Mount Sinai Hospital Pulmonary Function Laboratory
- Arthur Slutsky, CM, FRSC, MASc, MD Co-founder
Professor of Medicine, Surgery and Biomedical Engineering, University of Toronto; and, Scientist, Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
- Brigadier General (Ret.) Richard Tubb, MD
White House Physician Emeritus
- Dr. Eddie Wasser, MD, CCFP, DAAPM, DCAPM
Emergency and Critical Care Physician; and Executive Health Physician at the Cleveland Clinic- Specializing in Preventative Medicine
- Adam Hanft
Globally recognized business leader and brand strategist at Hanft Projects
- Andrew Kent
Private practice business lawyer
Join the movement
We invite you to stay updated on our development of a safer alternative, and help us spread the word about the importance of harm reduction and education to de-stigmatize nicotine. So smokers can get the healthy help they need.
